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Abstract
Objective
The objective of this selective EBM review is to determine whether or not transcutaneous vagal
nerve stimulation is an effective measure in reducing seizure frequency in adult patients with
pharmacoresistant epilepsy.
Study Design
This systematic review comprises a randomized controlled trial and an observational pilot study,
both published in 2014, as well as a double-blind randomized control trial published in 2016.
Data Sources
All articles were published and displayed in English. The articles were obtained via the PubMed
database.
Outcomes Measured
Reductions in average seizure frequency were analyzed based on data from patient seizure
diaries.6,7,8 Secondary outcomes, including quality of life and seizure severity, were measured
through the Quality of Life in Epilepsy-31 (QoLIE-31) and Liverpool Seizure Severity Scale
(LSSS), respectively.6,7,8
Results
Aihua et al. and Peijing et al. demonstrated a significant reduction in seizure frequency, as well
as significant improvements in QoLIE-31 and LSSS scores.6,8 Bauer et al. did not achieve
statistically significant reductions in seizure frequency compared to the control, nor did they
demonstrate significant improvements in the QoLIE-31 or LSSS scores.7
Conclusion
The results evaluated in this systematic review showed promise for the use of tVNS in the
treatment of pharmacoresistent epilepsy. However, due to conflicting data and study design
limitations, no definitive conclusion could be achieved at this time. Further study is required to
better characterize the efficacy of tVNS in reducing seizure burden.
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Introduction
Seizures are a condition of aberrant electrical activity in the brain which disrupt normal
physiologic processes. A person is considered to have epilepsy when multiple seizures occur
without an identified and reversible cause, such as alcohol withdrawal.1 While 5-10% of the
population will experience a seizure in their lifetime, only about 0.3-0.5% are affected by
epilepsy.2 Not only is this disease fairly common, it also carries a significant financial burden. A
2015 systematic review found annual per-patient epilepsy costs ranged from $1,022-19,749.3
Those with refractory disease are affected to an even greater degree, with costs over twice as
high as those with controlled epilepsy.4 Refractory patients also average 3.6 annual visits for
their epilepsy, compared to 2.2 for controlled, and are hospitalized roughly twice as often.4
The etiology of seizures is diverse and largely varies by age. Febrile seizures are most common
among young children and epilepsy in older children is often due to anatomical abnormalities or
developmental disorders.2 In adults and the elderly, head trauma and stroke are the most common
causes, respectively.2 Other causes include neoplasms, infections, metabolic disturbances and
autoimmune disorders.1 Only 10% of epileptics have generalized tonic-clonic seizures as their
main presentation.2 Others with generalized seizures present with brief impairment of
consciousness, as seen in absence seizures, or may have myoclonic or atonic episodes. Seizures
may also have a focal onset, which may cause motor symptoms or sensory abnormalities and
may or may not impair consciousness. Focal seizures also possess the potential to disseminate
from the affected area to both cerebral hemispheres, producing a generalized seizure.
The cornerstone of epilepsy treatment is prophylactic antiepileptic medications. While
indications for medications vary by seizure classification, common medications include
valproate and lamotrigine.4 Surgical resection of the problematic areas of the brain remains an
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option for those who have failed at least two medications.1 For those without well-defined
seizure foci, or that are poor surgical candidates, surgically implanted vagal nerve stimulation
(iVNS) exists.1 iVNS was approved by the FDA in 1997 and has been demonstrated to be a safe
and effective treatment, though is not without adverse reactions.5 The most common reactions
include cough and voice hoarseness5,6, but vocal cord paralysis and device infection remain rare
complications5. Transcutaneous VNS (tVNS) circumvents these adverse reactions by stimulating
the somatic branch of the vagus nerve via the Ramsay-Hunt zone of the ear.6 tVNS also avoids
the need for invasive surgical implantation and periodic battery replacements.6,7,8
Objective
The objective of this selective EBM review is to determine whether or not transcutaneous vagal
nerve stimulation is an effective measure in reducing seizure frequency in adult patients with
pharmacoresistant epilepsy.
Methods
The population of interest consists of men and women of at least 18 years of age with
pharmacoresistent epilepsy. This review compares tVNS to either stimulation of a nontherapeutic zone of the ear or to stimulation at a sub-therapeutic frequency. The efficacy of tVNS
was primarily evaluated via reduction in seizure frequency and secondarily through quality of
life improvement and reduction in symptom severity.
The Cochrane and Medline database searches were used to find articles relevant to the clinical
question that contained patient-oriented outcomes. Keywords used in searching included
epilepsy, seizures, transcutaneous electric nerve stimulation and vagus nerve stimulation. This
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Table 1: Demographics and Characteristics of Selected Studies
Study

Type

Aihua,
20146

RCT

Bauer,
20167

Peijing,
20148

RCT,
doubleblind

Observa
tional
Pilot
Study

#
Pts
60

76

50

Age (yrs)
Treatment
group
mean: 34.5
(IQR 26.5,
41.3)
Control
group
mean:
29.0 (IQR
24.5, 42.0)
18-65,
mean 38.8
± 12.5

25.2 ± 13.1

Inclusion
Criteria
> 4 years of age
> 4 seizures per
month
Taking ≥ 2 AEDs
over 2 years with
ineffective seizure
control
Unable or unwilling
to complete surgical
treatment

Exclusion
Criteria
Pregnant
Lactating
Serious heart, liver
or kidney disease
Implanted medical
devices
Could not tolerate tVNS for more than 6
months

W/D

Interventions

13

Bilateral
Ramsey-Hunt
zone tVNS

Age 18-65 years
Have epilepsy with
focal and/or
generalized seizures
≥ 3 seizures per
month
Stable regiment of ≤
3 AEDs for ≥ 5
weeks

≤ 21 consecutive
seizure-free days
> 1 episode of status
epilepticus within 6
months
Current or prior
treatment with iVNS
or DBS
Ablative epilepsy
surgery
History of nonepileptic seizures
Major Psychiatric
disorders
Deteriorating
neurological or
medical conditions
and/or relevant
cardiovascular
disease

18

Age 12-65 years
Frequent disabling
seizures, intractable
to treatment with ≥
1 AEDs for ≥ 1 year
Bilateral and/or nonlocalized findings,
not candidates for
surgical treatment
Valid record of the
patient’s daily
frequency of
seizures

Tumors, progressive
encephalopathy,
progressive
neurodegenerative
disorders and serious
pulmonary and heart
disease
Patients treated
concomitantly with
corticosteroids,
anxiolytics or
antidepressants

3

vs
Bilateral
earlobe tVNS

Therapeutic
unilateral
tVNS at 25 Hz
vs
Subtherapeutic
unilateral
tVNS at 1 Hz
(active control)

Triangular
fossa of the
auricle
Transcutaneou
s electrical
nerve
stimulation
(TENS)
(no
comparison,
observational
study)
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systematic review is comprised of a randomized controlled trial, a randomized double-blind
controlled trial and an observational pilot study. All evaluated articles were displayed in English
and contained published data. Inclusion criteria in the search included randomized controlled
trials or observational studies published between 2007 and the time of writing. Exclusion criteria
included studies with fewer than 50 participants. Reported statistics used include P-values, CIs
and mean change from baseline.
Outcomes Measured
The primary outcome measured in all articles was reduction in seizure frequency.6,7,8 This was
evaluated through seizure diaries kept by the patients and reported through surveys8 or follow-up
telephone correspondence6. Changes in quality of life were monitored through the Quality of
Life in Epilepsy-31 (QoLIE-31). This questionnaire utilizes a health-focused perspective, with
scores ranging from 0% to maximal quality of life at 100%.7 Changes in symptom severity were
monitored through the Liverpool Seizure Severity Scale (LSSS). As the name suggests, this 20question survey assesses seizure symptoms, with maximal symptoms given a score of 80.7
Results
Aihua et al. published a randomized controlled trial in 2014 in which 81 patients with
pharmacoresistent seizures were selected from Xuanwu Hospital in China. Patients were required
to have taken at least 2 antiepileptic drugs (AEDs) for at least 2 years with poor results and in
which surgery was not an option.6 Patients excluded from the study totaled 21, another 5 were
lost to follow up and an additional 8 discontinued due to adverse reactions.6 Of the 47 that
completed the study, 25 were female and 22 were male.6 Full inclusion and exclusion criteria
may be found in Table 1. The average age of the treatment and control groups were 34.5 (IQR:
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26.5 - 41.3) and 29.0 (IQR: 24.5 - 42.0), respectively.6 The most common seizure type was
simple partial at 68.1% of the study population.6 Complex partial seizures accounted for another
12.8%, and 19.1% had generalized seizures.6 The average length of epilepsy diagnosis, in years,
was 19.7 ± 11.1 in the treatment group and 17.6 ± 9.6 in the control group.6 Baseline seizure
frequency was 6.0 (IQR: 4.8 - 25.0) for the treatment group and 7.0 (IQR: 4.0 - 11.5) in the
control group.6 Each group was randomly assigned 30 patients.6 Those receiving treatment
underwent bilateral stimulation of the Ramsay Hunt zone of the ear at a frequency of 20 Hz with
a 0.2 s pulse width.6 Current was titrated up from 2 mA, as dictated by patient tolerance.6
Stimulation was continuous for 20 minutes, three times daily for 12 months.6 Control group
patients received the same stimulation, but of the earlobe.6 All patients were maintained on their
baseline antiepileptic regimen.6
The researchers found a significant reduction in seizure frequency, with median values at 5.5
(IQR: 3.0 - 12.0) at 6 months and 4.0 (IQR: 2.8 - 8.3) at 12 months.6 Despite these results, a
significant difference between the treatment and control groups was not observed until 12
months, where median seizure frequency was 4.0 (IQR: 2.8 - 8.3) and 8.0 (IQR: 4.5 - 12.0),
respectively.6 Results are summarized in Table 2. Significant improvements were also observed
in QoLIE-31 and LSSS scores after 12 months of treatment (P < 0.001, P = 0.001), though the
data were not published.6
Table 2: Reduction in Seizure Frequency in the Aihua Study6
Duration of
Therapy

Median Seizure
Frequency

Percent Reduction from
Baseline

P Value

6 Months

5.5 (IQR 3.0 - 12.0)

8.3%

P < 0.001

12 Months

4.0 (IQR 2.8 - 8.3)

33%

P < 0.001
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In 2016, Bauer published a double-blind randomized controlled trial that included 87 patients
from Germany and Austria.7 Selected patients had to have at least 3 monthly seizures and no
seizure-free period of greater than 21 days.7 Screening parameters deselected 11 patients and an
additional 18 discontinued the study due to non-compliance, withdrawal of consent, patient risk,
death or various other reasons.7 Full inclusion and exclusion criteria may be found in Table 1.
The mean age in years of the treatment group was 40.1 ± 12.7, compared to 37.5 ± 12.2 for the
control group.7 Partial seizures accounted for 71.1% of the patients.7 The average length of
epilepsy diagnosis was 23 years for the treatment group and 24.2 years for the control group.7 Of
those initially enrolled in the study, 45 were female and 31 were male.7 Patients were randomly
selected into the treatment and control groups, which initially contained 37 and 39 patients,
respectively.7 Those enrolled in the treatment group were subjected to unilateral stimulation at 25
Hz with a 0.25 s pulse width at cycles of 30 seconds on and 30 seconds off.7 Stimulation was
continued as described above for 4 hours daily for 20 weeks.7 Patients enrolled in the control
group received equivalent stimulation, but at a sub-therapeutic frequency of 1 Hz.7 Current was
titrated between perception of the stimulation and painful stimulation to an average of 1.02 ±
0.83 mA in the control group and 0.50 ± 0.47 mA in the treatment group.7 The antiepileptic
regimen of the patients remained constant throughout the study.7 Statistics were analyzed using
the ANCOVA model.7 Median compliance was found to be 93.3% for the control group and
96.7% for the treatment group.7
The study found LS-mean reductions in seizure frequency of approximately -2.9% (95% CI:
[-26.4%; 21.5%], p = 0.842) in the control group and 22.9% (95% CI: [-1.7%; 47.5%], P =
0.067) in the treatment group.7 Neither of these values demonstrated clinical significance.7
However, a significant reduction of 34.2% (P = 0.034) was observed in the 26 patients who
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completed the 20 weeks of stimulation.7 A 25.3% (95% CI; [-9.0%; 59.7%], P = 0.146)
difference in LS-mean was observed between the control and treatment groups at end of
treatment, though this value was also found to be insignificant.7 Results are summarized in Table
3. Average LSSS scores increased by 0.83 in the control group and 1.56 in the treatment group,
though only the change in the treatment group was found to be significant.7 No significant
difference was found between the groups.7 The QoLIE-31 values were also found to have
increased throughout the study by 4.65 and 2.68 in the control and treatment groups,
respectively.7 Only the control group difference was found to be significant.7 Again, no
difference was found between the groups.7 Results are summarized in Table 4.
Table 3: Reduction in Seizure Frequency in the Bauer Study7
Group

LS-Mean Reduction in Seizure
Frequency at 20 Weeks

95% CI

P Value

Control

-2.9%

[-26.4%; 21.5%]

P = 0.842

Treatment

22.9%

[-1.7%; 47.5%]

P = 0.067

Table 4: Change in LSSS and QOLIE-31 Scores at End of Treatment in the Bauer Study7
Group

Change in LSSS Score P Value
at End of Treatment

Change in QoLIE-31
Score at End of
Treatment

P Value

Control

0.83

P = 0.194

4.65

P = 0.01

Treatment

1.56

P = 0.017

2.68

P = 0.077

Published in 2014, Peijing et al. conducted an observational pilot study with 50 patients from
three Chinese hospitals.8 Patients included in the study had to have pharmacoresistent seizures
while taking at least 2 AEDs for at least 1 year.8 Full inclusion and exclusion criteria may be
found in Table 1. Over the course of the study, 3 discontinued due to adverse reactions.8 Of the
47 that completed the study, 28 were male and 19 were female.8 The average age of those
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participating in the study was 25.2 ± 13.1 years.8 84% of the participants suffered from complex
partial seizures, with the remaining 16% suffering from generalized seizures.8 The average
length of diagnosis of epilepsy was 12.0 ± 8.1 years and the average monthly seizure frequency
was 85.2 ± 14.4.8 All patients underwent unilateral stimulation of the triangular fossa of the
auricle for 30 minutes, twice daily, for a total of 24 weeks.8 Stimulation was accomplished at a
frequency of 20-30 Hz with a ≤ 1 ms pulse width and at 1 mA of current.8 Patients were
maintained on their baseline AED treatment for the duration of the study.8
The authors found a significant decrease in average seizure frequency of 51.3% (P < 0.01) after
24 weeks of treatment.8 This was improved from 46.6% (P < 0.01) at 16 weeks and 34.3% (P <
0.05) at 8 weeks of treatment.8 Significant improvement was also observed in the QOLIE-31
scores, with an increase of 4.4 (P < 0.001) at the end of treatment.8 Similarly, significant
improvements were seen in LSSS scores (P < 0.017), though the data were not reported.8
Table 5: Reduction in Seizure Frequency in the Peijing Study8
Duration of Therapy

Reduction in Seizure Frequency from Baseline

P Value

8 Weeks

34.3%

P < 0.05

16 Weeks

46.6%

P < 0.01

24 Weeks

51.3%

P < 0.01

Overall, tVNS was well tolerated over all three studies. Aihua et al. had 1 patient discontinue due
to dizziness and had 3 experience daytime drowsiness.6 Bauer et al. found headache to be the
most common treatment emergent adverse reaction.7 Other common reactions included ear pain,
erythema, fatigue, vertigo and nausea.7 A summary of all adverse reactions from this study is
detailed in Table 6. A total of 4 control group participants discontinued due to syncope,
palpitations, erythema and exacerbation of seizures.7 Another 3 treatment group participants
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discontinued due to vestibular neuronitis, basal cell carcinoma and headache/exhaustion/nausea.7
One patient passed away after a sudden unexplained death in epilepsy (SUDEP), which was
considered to be unrelated to tVNS treatment.7 Peijing et al. found similar results, with one
patient discontinuing due to dizziness.8 Another two patients reported having erythema and
edema.8
Table 6: Treatment Emergent Adverse Reactions in the Bauer Study7
Adverse Reaction
Headache

Control Group (n = 39)
N (%)
2 (5.1)

Treatment Group (n = 37)
N (%)
7 (18.9)

Ear Pain

2 (5.1)

6 (16.2)

Erythema

1 (2.6)

3 (8.1)

Vertigo

1 (2.6)

3 (8.1)

Fatigue

2 (5.1)

1 (2.7)

Nausea

1 (2.6)

2 (5.4)

Discussion
In this systematic review, the efficacy of transcutaneous vagal nerve stimulation (tVNS) was
evaluated in the reduction of seizure frequency and improvement of quality of life in patients
suffering from pharmacoresistent epilepsy. One of the randomized controlled trials and the
observational pilot study found statistically significant reduction in the average seizure frequency
of those enrolled.6,8 The double-blind RCT did not find statistically significant reductions in
seizure frequency overall but did find significant improvements in the subset of participants that
completed the full study period.7 Similarly, the former two studies found statistically significant
improvements in QoLIE-31 and LSSS scores.6,8 The later study demonstrated conflicting
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evidence, finding significant improvement of the QoLIE-31 scores only in the control group and
statistically worse LSSS scores in the treatment group.7
Comparing the three trials, efficacy was directly related to treatment duration.6,7,8 This suggests a
greater benefit may be observed in patients over time as they continue with therapy.
Interestingly, efficacy was found to be inversely related to both length of diagnosis and to
average age of participant when comparing results to population demographics between the three
studies.6,7,8 This may suggest tVNS therapy is more effective when started earlier in the disease
process, when patients are younger.
The most significant limitation of all three studies was the subjectivity of patient-recorded
seizure diaries and surveys. The utilization of objective measures, such as ambulatory EEG
monitoring, may yield more conclusive results in future studies. In addition, the Aihua study
utilized bilateral stimulation, which may have magnified efficacy relative to the other studies,
which used unilateral stimulation.6,7,8 The authors also noted the study population contained a
sample size too small to be able to compare efficacy against various AEDs.6 The study also had a
fairly high dropout rate at 22%, which may have impacted the end results.6 While this study
demonstrated high precision in terms of statistical significance, the IQRs reported were wide,
indicating substantial variability among the subjects.6 In the Bauer study, the researchers had to
utilize higher current in the control stimulation to ensure blinding, which may have artificially
reduced the observed difference between treatment and control groups.7 They also noted that
while medication regimens were maintained, approximately 33% of those enrolled were not on
an AED throughout the study, limiting the comparability to the other studies included.7 This
study also had a high dropout rate at 24%.7 In the Peijing study, the major limitations were that
the study was not blinded or controlled.8
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Currently, there are no tVNS devices that are FDA approved for the treatment of seizures. This is
reflected in the paucity of research available from the US, which was a major factor in the
selection of studies with mainly Chinese6,8 and German7 populations. However, the gammaCore
tVNS system was FDA approved in 2017 for cluster headaches and in 2018 for migraine
headaches.9 The tVNS device is also currently being researched for other diagnoses, including
heart failure10, depression11 and autism12. Alternative methods of neurostimulation are also under
investigation, including trigeminal nerve stimulation (TNS), deep brain stimulation (DBS) and
the responsive neurostimulation system (RNS).5
Conclusion
The evidence appears inconclusive as to whether tVNS is effective in reducing seizure burden in
those with pharmacoresistent epilepsy. The Peijing and Aihua studies found significant
reductions in average seizure frequency at end of treatment ranging from 33-51%.6,8 However,
the Peijing study was not a randomized controlled trial8 and Bauer et al. did not observe a
significant reduction in seizure frequency7. Nevertheless, the results are promising, and the
Bauer study did find a significant reduction among the participants that were able to complete
the trial.7 Due to these results and the relatively benign side effect profile, further research is
warranted to better characterize the effectiveness of tVNS in reducing seizure burden. Future
studies will benefit from increased sample sizes and greater diversity of geographical regions.
Furthermore, as a direct relationship was observed between length of treatment and efficacy,
longer trials may be necessary to observe maximal efficacy. Finally, greater standardization of
patient demographics, study design and treatment modality may help to confirm the efficacy of
tVNS and determine which patient populations are of greatest benefit.
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